• Publications
  • Influence
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.
TLDR
Overexpression of Brachyury in human carcinoma cells induced changes characteristic of EMT, including upregulation of mesenchymal markers, downregulation of epithelial markers, and an increase in cell migration and invasion. Expand
IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.
TLDR
The results emphasize the potential role of EMT in the modulation of the tumor microenvironment via secretion of multiple soluble mediators and suggest that IL-8 signaling blockade may provide a means of targeting mesenchymal-like, invasive tumor cells. Expand
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
TLDR
The dual potential roles that the inflammatory cytokine IL-8 plays in promoting tumor resistance by enhancing the immunosuppressive microenvironment and activating EMT are highlighted, and the potential for targeting the IL- 8/IL-8 receptor axis to combat these various resistance mechanisms is discussed. Expand
Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.
TLDR
Current knowledge on the secretory properties of epithelial tumor cells that have undergone an EMT are summarized, with an emphasis on the potential role of the IL-8-IL-8 receptor axis on the induction and/or maintenance of tumor EMT and its ability to remodel the tumor microenvironment. Expand
WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.
TLDR
It is suggested that reconstituting CDK1 activity to threshold levels may be sufficient to restore immunosurveillance of mesenchymal-like cancer cells that have escaped previous immune detection or eradication. Expand
Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
TLDR
The ability of Brachyury-specific T-cell lines to lyse Brachyura-positive tumor cells, in vitro, supports the development of Brachesury-based immunotherapeutic approaches for the treatment of lung cancer. Expand
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
TLDR
The MVA-brachyury-TRICOM vaccine directed against a transcription factor known to mediate EMT can be administered safely in patients with advanced cancer and can activate brachyuries-specific T cells in vitro and in patients. Expand
Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.
TLDR
Analysis of publicly available datasets and immunohistochemical analysis of primary and metastatic tumor biopsies from TNBC patients were conducted to evaluate the expression of the transcription factor brachyury, which is a driver of tumor metastasis and resistance and a target for cancer vaccine approaches. Expand
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
TLDR
This is the first vaccine platform aimed at targeting a driver of tumor EMT that has successfully reached the clinical stage and it is demonstrated that human dendritic cells treated with recombinant yeast-brachyury can activate and expand brachyury-specific CD4+ and CD8+ T cells in vitro that, in turn, can effectively lyse human tumor cells expressing the Brachyury protein. Expand
Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.
TLDR
The studies reported here provide the rationale for the use of a vaccine targeting brachyury for the therapy of human breast cancer, either as a monotherapy or in combination therapies. Expand
...
1
2
3
4
5
...